Loading
Tests for 'HRD', which decide who gets PARP inhibitors, rely on genomic scars that reflect the tumour's past, not its present. A test of current DNA-repair function would be better, but needs standardising.
Genomic scar assays (for example the Myriad myChoice score) predict PARP inhibitor benefit imperfectly and remain positive after resistance develops. Functional assays (RAD51 foci formation on tissue) measure current repair capacity and have shown promise in retrospective series. A consortium to standardise the RAD51 assay (antibodies, scoring, reference tissue) and validate it prospectively in a PARP inhibitor trial would give a dynamic, mechanism-based biomarker.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares HRD & BRCA testing, PARP, PARP inhibitors, Olaparib.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares HRD & BRCA testing, Homologous recombination deficiency (HRD), PARP, PARP inhibitors.
Shares HRD & BRCA testing, Homologous recombination deficiency (HRD), PARP, PARP inhibitors.
Shares HRD & BRCA testing, Homologous recombination deficiency (HRD), PARP, PARP inhibitors.
Shares Homologous recombination deficiency (HRD), PARP, Olaparib, Ovarian cancer.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).